JRCT ID: jRCT2031240338
Registered date:17/09/2024
Ezharmia Tablet Post-marketing Surveillance
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | peripheral T-cell lymphoma: (PTCL) |
| Date of first enrollment | 24/06/2024 |
| Target sample size | 150 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Cumulative incidence of AEs (safety specifications : myelosuppression,infection and the secondary malignancy of the survey) and other AEs |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | All patients who start receiving Ezharmia Tablet during the registration period. |
| Exclude criteria | None |
Related Information
| Primary Sponsor | Tanabe Hirokazu |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | GPSP for Contact |
| Address | 3-5-1,Nihonbashi Honcho,Chuo-ku,Tokyo Tokyo Japan 103-8426 |
| Telephone | +81-3-6225-1059 |
| contact_gpsp@daiichisankyo.co.jp | |
| Affiliation | Daiichi Sankyo Co.,Ltd. |
| Scientific contact | |
| Name | Hirokazu Tanabe |
| Address | 3-5-1,Nihonbashi Honcho,Chuo-ku,Tokyo Tokyo Japan 103-8426 |
| Telephone | +81-3-6225-1059 |
| contact_gpsp@daiichisankyo.co.jp | |
| Affiliation | Daiichi Sankyo Co.,Ltd. |